Navigation Links
Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device

ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire/ -- Terumo Cardiovascular Systems announced today that it has entered into an exclusive agreement with LAAx, Inc. to distribute the TigerPaw® System II, a left atrial appendage closure device in the U.S.

The TigerPaw System II is indicated for occlusion of the left atrial appendage under direct visualization, in conjunction with other open cardiac procedures.  It is new to the market following successful completion of a clinical trial.  During its clinical trial the TigerPaw System II provided 100% occlusion at both post-op and at 90 days.

Mark Sutter, President and CEO of Terumo Cardiovascular Systems, stated, "This expansion of our product portfolio is another example of Terumo CVS's commitment to the CV OR market.  The distribution agreement provides us with an excellent product that provides advantages over other offerings on the market and that cardiac surgeons need today.  We are proud of this new partnership with LAAx, Inc."

Bill Wheeler, President and CEO of LAAx, Inc., added, "Terumo's broad distribution network will be a tremendous asset.  We will work together to get the TigerPaw System II into the hands of cardiac surgeons who have not yet had access to a clinically proven, 100% occlusive left atrial appendage (LAA) closure device. This clinical outcome expectation will benefit patients who need to reduce the medical risks associated with a less than 100% closure of the LAA.  We are happy to offer that option. Risk mitigation is an important consideration for every cardiac surgeon who considers 100% occlusion to be the only acceptable medical outcome for LAA occlusion technologies."

About Terumo Cardiovascular Systems Corporation 
Terumo Cardiovascular Systems Corporation manufactures and markets medical devices for the global cardiac surgery market and is the U.S. distributor for Vascutek® Vascular Grafts. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in Ann Arbor; Elkton, Maryland; and Ashland, Massachusetts. It is one of several subsidiaries of Terumo Corporation of Japan which focus on cardiac and vascular specialties, including Terumo Heart, Inc., developer of a ventricular assist device and Vascutek, Ltd., manufacturer of a broad portfolio of vascular grafts. For more information, visit

About LAAx, Inc.
LAAx, Inc. is a medical device company, located in Livermore, CA, whose purpose is to develop leading edge technology for the effective occlusion and/or exclusion of the left atrial appendage. Additionally, LAAx, Inc. is committed to maintaining effective systems to manage quality and quality objectives which translate technology into medical devices that are safe, serve the needs of the patient and the physician, and provide a viable business opportunity. LAAx, Inc.'s global goal is to make a positive impact on both the quality and effectiveness of healthcare delivered worldwide.


SOURCE Terumo Cardiovascular Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Americas Holding Acquires Onset Medical Corporation, a Leader in Innovative Sheath Technology Designed for Multiple, Minimally Invasive Clinical Applications
2. Terumo Corporation, A Global Leader In Medical Device Technology, Celebrates 90th Anniversary
3. FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
4. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
5. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
6. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
7. Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
8. Terumo to Sponsor Presentations on Key Issues in Cardiac and Vascular Surgery at Society of Thoracic Surgeons Annual Meeting
9. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
10. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
11. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
Post Your Comments:
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):